Abstract
Pharmaceutical industry becomes more and more important because of the global average life and populations are getting growth continually. However, the top selling pharmaceutical companies in American and Japanese, Pfizer and Takeda, both face the biggest problem about off-patent of their blockbusters which would affect their sales seriously. They should increase their drugs and product lines to solve it. But research and developing new drugs need lots of time and cost, so large pharmaceutical companies especially Pfizer use merger and acquisition at the same time to get new blockbusters. And Takeda also uses alliance to cooperate with other authorities. The biggest difference between the two companies is the degree of internationalization. The purpose of this thesis is analyzing the top selling American and Japanese pharmaceutical companies through Hamel's business model, and discusses the differences between the two companies. And then giving some advises to Taiwan pharmaceutical industry to realize what strategy or action can be taken. Pharmaceutical industry becomes more and more important because of the global average life and populations are getting growth continually. Hoping this research about analyzing pharmaceutical companies of advanced countries can bring some contributions developed pharmaceutical industry of Taiwan.
| Translated title of the contribution | Exploring the Development of the Pharmaceutical Industry in Taiwan from the Business Models of Pfizer and Takeda Pharmaceutical Companies |
|---|---|
| Original language | Chinese (Traditional) |
| Pages (from-to) | 24+26-43 |
| Journal | 產業與管理論壇 = Industry and Management Forum |
| Volume | 15 |
| Issue number | 1 |
| Publication status | Published - 2013 Mar 1 |